Onvitrelin ucalontide

Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model[1][2].

NCCCC[C@H](N)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC5=CC=CC=C5)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC6=CN=CN6)C(N[C@H](C(N[C@@H](CO)C(N[C@H](C(NCC(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N7[C@@H](CCC7)C(NCC(O)=O)=O)=O)=O)=O)=O)CC8=CC=C(C=C8)O)=O)=O)CC9=CNC%10=CC=CC=C9%10)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

[1]Leuschner Carola, et al. Lytic domain fusion constructs and methods of making and using same for treating cell proliferation disorders: World Intellectual Property Organization, WO2009094634. 2009-07-30.|[2]WHO Drug Information-World Health Organization (WHO).